Concepedia

Sophie Shifman

SS

Statistics

Publications

7

Citations

962

H-Index

7

Active since

2018

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Cornell University

Molecular Oncology (United States)

Candiolo Cancer Institute

Puma Biotechnology (United States)

Sophie Shifman is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and molecular oncology.

ORCID

Publications per year

2018–2022

7

Publications

7

HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers

Bob T. Li, Flavia Michelini, Sandra Misale et al. · Cancer Discovery · 2020 · 289 citations · Full text

, , +17

Resistance to TRK inhibition mediated by convergent MAPK pathway activation

Emiliano Cocco, Alison M. Schram, Amanda Kulick et al. · Nature Medicine · 2019 · 226 citations · Full text

, , +13

TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations

Ezra Y. Rosen, Debra A. Goldman, Jaclyn F. Hechtman et al. · Clinical Cancer Research · 2019 · 155 citations · Full text

, , +16

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

Ezra Y. Rosen, Helen Won, Youyun Zheng et al. · Nature Communications · 2022 · 114 citations · Full text

, , +17

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

Emiliano Cocco, F. Javier Carmona, Pedram Razavi et al. · Science Signaling · 2018 · 73 citations · Full text

, , +17

1–5 of 7